Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include common findings: Cataract, Amblyopia, Iris coloboma, and Damage to the optic nerve (optic atrophy) and others; and sometimes findings: Lens subluxation.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Lens subluxation, Cataract, Amblyopia |
ELP4 encodes elongator acetyltransferase complex subunit 4 (424 aa). Component of the elongator complex which is required for multiple tRNA modifications, including mcm5U (5-methoxycarbonylmethyl uridine), mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine), and ncm5U (5-carbamoylmethyl uridine). Highest expression in Brain Cerebellar Hemisphere (4.7 TPM) and Brain Cerebellum (4.1 TPM).
Aniridia 2 is associated with mutations in the ELP4 gene on chromosome 11.
ELP4 is classified as a druggable target with score 0.0.
Genetic testing for ELP4 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 5 common features.
No clinical trials have been registered for aniridia 2.
86 publications have been identified in PubMed for aniridia 2. Research spans Basic Science / Preclinical (33%), Case Report / Case Series (22%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 28 | 33% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 3:44 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about aniridia 2
1 |
Damage to the optic nerve (optic atrophy) |
19 |
22% |
Disease patterns and progression | 16 | 19% |
Clinical study results | 11 | 13% |
Research summaries | 9 | 10% |
Other research | 2 | 2% |
New treatment approaches | 1 | 1% |
Willems M (2026). [PMID: 42204496](https://pubmed.ncbi.nlm.nih.gov/42204496/). *BMC Ophthalmol*. [Basic Science / Preclinical]
Research on rare and intractable diseases, Health, Labour and Welfare Sciences Research Grants Clinical Practice Guideline Development Committee for Aniridia of the “Research group on establishing standardized diagnosis and treatment of Intractable corneal diseases” (2026). [PMID: 41903000](https://pubmed.ncbi.nlm.nih.gov/41903000/). *Jpn J Ophthalmol*. [Other]
George AM (2026). [PMID: 41968606](https://pubmed.ncbi.nlm.nih.gov/41968606/). *Am J Med Genet A*. [Epidemiology / Natural History]
Peretz D (2026). [PMID: 40100048](https://pubmed.ncbi.nlm.nih.gov/40100048/). *Cornea*. [Epidemiology / Natural History]
Amini M (2026). [PMID: 42048350](https://pubmed.ncbi.nlm.nih.gov/42048350/). *PLoS One*. [Basic Science / Preclinical]
Marjani N (2026). [PMID: 41915678](https://pubmed.ncbi.nlm.nih.gov/41915678/). *Cornea*. [Case Report / Case Series]
Research on rare and intractable diseases, Health, Labour and Welfare Sciences Research Grants Clinical Practice Guideline Development Committee for Aniridia of the “Research group on establishing standardized diagnosis and treatment of Intractable corneal diseases” (2026). [PMID: 41954827](https://pubmed.ncbi.nlm.nih.gov/41954827/). *Jpn J Ophthalmol*. [Other]
Tóth G (2026). [PMID: 41276206](https://pubmed.ncbi.nlm.nih.gov/41276206/). *American journal of ophthalmology*. [Review / Meta-Analysis]
Liu S (2026). [PMID: 41525419](https://pubmed.ncbi.nlm.nih.gov/41525419/). *PloS one*. [Basic Science / Preclinical]
Hsu SL (2026). [PMID: 42251340](https://pubmed.ncbi.nlm.nih.gov/42251340/). *BMC Ophthalmol*. [Gene Therapy / Novel Therapeutics]